Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation volume 26, pages 1247–1249 (2000)Cite this article

Abstract

This report describes two patients with germ cell tumors who underwent tandem autologous peripheral stem cell transplants. The chemotherapy consisted of high-dose carboplatin and etoposide. Both patients developed chemotherapy-related toxicities, which included nephrotoxicity in one case and febrile neutropenia, thrombocytopenia, ototoxicity and mucositis in both. During the second transplant, both patients received amifostine 15 min before and 2 h after each dose of carboplatin. The patients had less mucositis and nephrotoxicity. The duration of neutropenia and thrombocytopenia was less in both cases resulting in a decreased use of antibiotics and platelet transfusions. These cases suggest that the use of amifostine may be of benefit in minimizing toxicities associated with high-dose chemotherapy. Bone Marrow Transplantation (2000) 26, 1247–1249.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Broun ER, Nichols CR, Gize G et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer Cancer 1997 79: 1605–1610

    Article  CAS  Google Scholar 

  2. Broun ER, Nichols CR, Mandanas R et al. Dose escalation study of high-dose carboplatin and etoposide with autologous marrow support in patients with recurrent and refractory germ cell tumors Bone Marrow Transplant 1995 16: 353–358

    CAS  PubMed  Google Scholar 

  3. Capizzi RL . Clinical status and optimal use of amifostine Oncology 1999 13: 47–59

    CAS  PubMed  Google Scholar 

  4. Markman M . Amifostine in reducing cisplatin toxicity Semin Oncol 1998 25: 522–524

    CAS  PubMed  Google Scholar 

  5. Capizzi RL . Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects Semin Oncol 1999 26: 72–81

    CAS  PubMed  Google Scholar 

  6. Alberts DS, Bleyer WA . Future development of amifostine in cancer treatment Semin Oncol 1996 23: (Suppl. 8) 90–99

    CAS  PubMed  Google Scholar 

  7. Loehrer PJ Sr, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 1998 16: 2500–2504

    Article  Google Scholar 

  8. Motzer RJ, Cooper K, Geller NL et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors Cancer 1990 66: 2476–2481

    Article  CAS  Google Scholar 

  9. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer J Clin Oncol 1996 14: 2101–2112

    Article  CAS  Google Scholar 

  10. Korst AE, van der Sterre ML, Eeltink CM et al. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors Clin Cancer Res 1997 3: 697–703

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood and Marrow Stem Cell Transplantation Program, College of Pharmacy, University of Michigan Medical Center, Ann Arbor, MI, USA

    S Cronin & C Raith

  2. Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA

    JP Uberti, LJ Ayash & V Ratanatharathorn

Authors
  1. S Cronin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JP Uberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. LJ Ayash
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Raith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Ratanatharathorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cronin, S., Uberti, J., Ayash, L. et al. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 26, 1247–1249 (2000). https://doi.org/10.1038/sj.bmt.1702694

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702694

Keywords

This article is cited by

Search

Advanced search

Quick links